Dupilumab after the 2017 approval for the treatment of atopic dermatitis: whatʼs new and whatʼs next?

Purpose of reviewThe IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling new data regarding dupilumab published following the approval.Recent findingsDaily clinical practice reports of dupilumab in atopic dermatiti